Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docetaxel/encequidar - Athenex

Next Previous
X
Search
Drug Profile

Docetaxel/encequidar - Athenex

Alternative Names: Docetaxel + HM-30181A; Docetaxel + HM30181AK-US; Docetaxel oral/encequidar oral- Athenex; Encequidar/Docetaxel - Athenex; Oradoxel

Latest Information Update: 04 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex; Hanmi Pharmaceutical
  • Class Amides; Antineoplastics; Benzopyrans; Isoquinolines; Small molecules; Taxanes; Tetrazoles
  • Mechanism of Action Mitosis inhibitors; P-glycoprotein inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 04 Apr 2022 Discontinued - Phase-I for Cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (PO) (Hanmi Pharmaceutical pipeline, April 2022)
  • 04 Apr 2022 Discontinued - Phase-I for Prostate cancer (Metastatic disease) in New Zealand (PO) (Hanmi Pharmaceutical pipeline, April 2022)
  • 04 Apr 2022 Discontinued - Phase-I for Prostate cancer (Metastatic disease) in Taiwan (PO) (Hanmi Pharmaceutical pipeline, April 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top